Legend Biotech Announces Attendance at Upcoming Investor Conferences |  business Finance

Legend Biotech Announces Attendance at Upcoming Investor Conferences | business Finance

SOMERSET, NJ – (BUSINESS WIRE) – May 6, 2022–

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotech company that develops, manufactures and markets new therapeutics for the treatment of life-threatening diseases, today announced its participation in upcoming investor conferences:

Event: Bank of America Securities 2022 Healthcare Conference

Date and time of submission: Wednesday, May 11, 2022 at 5:20 pm PT / 8:20 pm ET

Position: Las Vegas, Nevada

Announcer: Ying Huang, Ph.D., CEO

Event: Jefferies Global Health Care Conference

Presentation date and time: Wednesday, June 8, 2022 at 1pm PT / 4pm ET

Location: New York, New York

Presenter: Ying Huang, Ph.D., CEO

Event: Goldman Sachs Annual Global Health Care Conference

Date and time of submission: Wednesday, June 15, 2022 at 1:20 pm PT / 4:20 pm ET

Position: Rancho Palos Verde, California

Announcer: Ying Huang, Ph.D., CEO

Legend Biotech is a global biotechnology company dedicated to the treatment and cure of life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies on a wide range of technology platforms, including autologous and allogeneic chimeric antigen receptor T cells, T cell receptor T cells (TCR-T) and natural cells. killer (NK). based immunotherapy. From our three research and development sites around the world, we apply these innovative technologies to pursue the discovery of safe, effective and cutting-edge therapies for patients around the world.

Statements in this press release about future expectations, plans and prospects, as well as any other statements relating to matters that are not historical facts, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but do not are limited to, statements relating to Legend Biotech’s strategies and objectives; CARVYKTI ™ related statements, including Legend Biotech’s expectations for CARVYKTI ™, such as Legend Biotech’s manufacturing and marketing expectations for CARVYKTI ™ and the potential effect of CARVYKTI ™ treatment; statements on cilta-cel submissions and the progress of such submissions to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the National Medical Products Administration’s Center for Drug Evaluation of China ( CDE) and other regulatory authorities; the anticipated timing and ability to progress clinical trials, including patient enrollment; submitting Investigational New Drug (IND) applications and maintaining such applications with regulatory authorities; the ability to generate, analyze and present data from clinical trials; and the potential benefits of Legend Biotech’s candidate products. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “can”, “plan”, “potential”, “foresee”, “plan” ” should “,” target “,” will “,” would “and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by these forward-looking statements due to various important factors. Legend Biotech’s expectations could be affected, among other things, by the uncertainties associated with the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analyzes of existing clinical data or unexpected new clinical data; regulatory actions or unforeseen delays, including requests for additional safety and / or efficacy data or data analysis, or government regulations in general; unexpected delays as a result of actions taken or failure to act by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including uncertainties involved in the US litigation process; competition in general; government, industry and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and the government and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report filed with the Securities and Exchange Commission on March 31, 2022. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect , actual results may differ materially from those described in this press release as expected, believed, estimated or expected. Any forward-looking statements contained in this press release are only effective as of the date of this press release. Legend Biotech expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investor Contacts:

Joanne Choi, Senior Manager, Investor Relations, Legend Biotech

Tina Carter, Corporate Communications Manager, Legend Biotech

KEYWORD: UNITED STATES NORTH AMERICA NEVADA CALIFORNIA NEW YORK NEW JERSEY

KEYWORD OF THE SECTOR: RESEARCH INFECTIOUS DISEASES STEM CELLS OTHER HEALTH BIOTECHNOLOGIES GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCES OTHER SCIENCES

Copyright Business Wire 2022.

PUB: 05/06/2022 16: 01 / DISCO: 05/06/2022 16:02

Copyright Business Wire 2022.

.

Leave a Comment

Your email address will not be published.